Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Epinephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 0.96 |
| ▸ | ADRB1 known ✓ | P08588 | 6/20 | 0.96 |
| ▸ | ADRB3 known ✓ | P13945 | 5/20 | 0.96 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.96 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.96 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.96 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.96 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 0.96 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.96 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.96 |
| ▸ | MAPT | P10636 | 6/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.96 |
| ▸ | TSHR | P16473 | 5/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.96 |
| ▸ | MEN1 | O00255 | 3/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.96 |
| ▸ | MTOR | P42345 | 3/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racepinephrine SCHEMBL28308045 | 1.00 | KDM4E (0.96) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Epinephrine SCHEMBL660960 | 0.98 | KDM4E (0.96) | KDM4ETDP1ADRB2HIF1AMAPT | |
| [11C]Epinephrine SCHEMBL29371663 | 0.98 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| [11C]Epinephrine SCHEMBL29374823 | 0.98 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Racepinephrine SCHEMBL29396039 | 0.98 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Epinephrine SCHEMBL29353423 | 0.98 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| L-Adrenaline SCHEMBL11647 | 0.98 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Racepinephrine SCHEMBL3815 | 0.98 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Racepinephrine SCHEMBL20493843 | 0.98 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Epinephrine SCHEMBL2837188 | 0.98 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11389171-B2 | Integrated system for the infixion and retrieval of implants | GOLDSMITH DAVID S (US) | 2022-07-19 | — | — | US | disclosed |
| US-11213496-B2 | Methods of using dipivefrin | Insignis Therapeutics, Inc. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210145445-A9 | Integrated system for the infixion and retrieval of implants | GOLDSMITH DAVID S (US) | 2021-05-20 | — | — | US | disclosed |
| US-20190247050-A1 | Integrated system for the infixion and retrieval of implants | GOLDSMITH DAVID S (US) | 2019-08-15 | — | — | US | disclosed |
| US-20190076378-A1 | METHODS OF USING DIPIVEFRIN | Insignis Therapeutics, Inc. | 2019-03-14 | — | — | US | disclosed |
| US-20090311795-A1 | BILATERAL CONTROL OF FUNCTIONS TRADITIONALLY REGULATED BY ONLY SEROTONIN OR ONLY DOPAMINE | Vidas, Arrett & Steinkraus, P.A. | 2009-12-17 | — | — | US | disclosed |
| WO-2009152426-A1 | BILATERAL CONTROL OF FUNCTIONS TRADITIONALLY REGULATED BY ONLY SEROTONIN OR ONLY DOPAMINE | HINZ MARTIN (US) | 2009-12-17 | — | — | WO | disclosed |
| US-5688936-A | ISOLATED DNA MOLECULE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-11-18 | — | — | US | disclosed |
| WO-1993025699-A1 | VESICLE MEMBRANE TRANSPORT PROTEINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1993-12-23 | — | — | WO | disclosed |
| US-3985897-A | GLAUCOMA | MEAD JOHNSON & COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
| US-3933998-A | 4-[2-(Isopropylamino)ethyl]pyrocatechol intraocular pressure lowering process | MEAD JOHNSON & COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190076378-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | ADRB2 138/4885ADRB1 114/4885ADRB3 55/4885 |
| US-11213496-B2 | Methods of using dipivefrin | QDPR, DNPEP, DPEP1 | ADRB2 138/4885ADRB1 114/4885ADRB3 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.